IMGN-779 shows a compelling clinical option for relapsed/refractory leukemia arena. This unique bare immunoglobulin specifically targets CD33, the antigen present on nearly all immature myeloid cells. Distinct from https://www.targetmol.com/compound/anti_cd33_antibody__imgn_779_naked_antibody_